Call to Schedule Free Consultation at Over 80 Centers Worldwide!

(844) GET-STEM

Stem Cell Therapy for Multiple Sclerosis: What a 9-Trial Meta-Analysis Reveals

Written by Dr. David Greene, MD, PhD, MBA on May 10, 2026

Table of Contents

Multiple sclerosis is a chronic autoimmune disease in which the immune system attacks the myelin sheath protecting nerve fibers in the brain and spinal cord. Symptoms range from walking difficulty and fatigue to cognitive changes and progressive disability.

Most approved therapies slow MS but do not reverse existing damage. That gap has driven serious scientific interest in stem cell therapy as a potentially restorative approach. In 2024, a meta-analysis published in Scientific Reports pooled nine randomized controlled trials involving 422 patients to evaluate the evidence. This article breaks down what was found, what remains uncertain, and what patients should know.

What the 2024 Meta-Analysis Found

Study Design

Researchers searched four major medical databases through January 2024, identifying nine qualifying RCTs with 422 MS patients. The analysis examined both mesenchymal stem cells (MSCs) and autologous hematopoietic stem cell transplantation (AHSCT) across multiple MS subtypes.

Disability Score Improvements

The key outcome measure was the Expanded Disability Status Scale (EDSS), which tracks neurological disability with a strong focus on walking ability.

Stem cell transplantation produced a statistically significant 0.57-point EDSS improvement at two months. For patients experiencing a steady decline, even modest gains are clinically meaningful. EDSS improvements at six and twelve months did not reach statistical significance in the pooled data — likely a reflection of short follow-up periods rather than loss of effect, though longer-term studies are needed to confirm this.

Brain Lesion Reduction

Stem cell therapy produced a highly significant reduction in brain lesion volume on MRI (mean reduction of 7.05 units; p = 0.0002). Lesion reduction reflects suppression of active inflammation and is a key marker of disease activity control in MS.

Safety

The most common side effects were temporary fever, headache, and dizziness. More significant events — localized infusion site reactions and blood-related effects in AHSCT patients receiving prior immunosuppression — were documented but uncommon. The overall short-term safety profile was acceptable across studies.

Types of Stem Cells Used in MS Research

Mesenchymal Stem Cells (MSCs) Mesenchymal stem cells are derived from bone marrow or fat tissue and work primarily by calming the immune system and supporting nerve repair. They are the most widely studied cell type in MS clinical trials and carry a relatively favorable safety profile.

Autologous Hematopoietic Stem Cell Transplantation (AHSCT) Uses the patient's own blood-forming stem cells following high-dose immunosuppressive therapy to effectively reset the immune system. More potent — and higher risk — than MSC therapy. Best studied in aggressive relapsing MS in younger patients earlier in their disease. Learn more about the pros and cons of autologous stem cells before exploring this route.

How Stem Cell Therapy Is Delivered

Intravenous (IV) Infusion Cells are delivered through a standard IV line, producing systemic immune-modulating effects. Minimally invasive with a well-documented safety profile across trials. To understand how stem cell therapy works at the biological level, the mechanism involves both immune modulation and tissue signaling.

Intrathecal (IT) Injection Cells are injected directly into the cerebrospinal fluid surrounding the spinal cord — the reverse of a standard spinal tap. This delivers cells closer to the central nervous system. In a recent progressive MS study, 60% of intrathecally treated patients showed major reductions in a key nerve damage biomarker versus 7% on placebo, with most also showing stable or improved EDSS scores at six and twelve months. R3 Stem Cell offers intrathecal stem cell treatment at select international centers.

Some providers combine both routes in a single treatment cycle to target both systemic immune activity and direct neurological repair simultaneously.

What the Evidence Does and Does Not Show

Supported by current evidence:

Significant disability improvement at two months

Acceptable short-term safety profile

Consistent immune-modulating effects

Reduced relapse rates and NEDA achievement in observational studies

Still uncertain:

Whether functional gains last beyond six months

A subset of patients in some studies showed no benefit or worsening over longer follow-up

Which subtypes and disease stages respond best

Optimal cell dose, timing, and delivery route

Direct comparison with newer high-efficacy disease-modifying therapies

Understanding how the body reacts to stem cell injections can help patients set realistic expectations about timing and response.

MS Subtypes and Candidacy

RRMS: Most evidence exists here. MSC therapy has shown reduced relapse frequency, lower MRI lesion activity, and decreased inflammatory immune markers.

SPMS: Disability accumulates steadily. Intrathecal delivery shows early promise; some trials report improved walking and muscle strength.

PPMS: The hardest to treat due to predominantly neurodegenerative rather than inflammatory mechanisms. Research is ongoing; results are more limited.

Progressive MS in general presents a higher treatment challenge. Current evidence favors earlier intervention when inflammatory activity is still prominent. Patients with autoimmune diseases broadly have shown benefit from stem cell approaches in the clinical literature.

R3 Stem Cell: Clinical Experience With MS

R3 Stem Cell operates more than 80 centers across eight countries and has performed over 28,000 procedures over the past decade, reporting an 85% overall patient satisfaction rate.

Their MS protocol uses combined IV and intrathecal delivery, consistent with the dual-route approach studied in published literature. Clinically, many patients report sustained benefits for 12 to 18 months before considering repeat treatment, with side effects that are mild, temporary, and consistent with what trials have documented.

For patients exploring international treatment options, R3 operates centers in multiple countries. Those in North America can also review stem cell treatment in Mexico as an accessible option.

Provider clinical experience is informative but different from controlled trial data. Patients should ask any provider what cell type is used, how outcomes are tracked, and what published evidence supports the protocol. Reviewing how to choose a stem cell clinic is a helpful first step.

Questions to Ask Before Pursuing Treatment

What cell type is used and where does it come from?

Are the cells from my own body or a donor?

What does the procedure involve and how long does recovery take?

How are outcomes monitored after treatment?

What can I realistically expect given my MS subtype and disability level?

Am I eligible for any active clinical trials?

For a broader framework, R3 has published a guide on questions to ask before a regenerative procedure that patients find useful before their first consultation.

The Bottom Line

The 2024 meta-analysis provides real, peer-reviewed evidence that stem cell therapy can improve disability and reduce brain lesions in MS — findings worth taking seriously. At the same time, studies were small, follow-up was short, and outcomes varied. Stem cell therapy is not a proven cure, but it is a legitimate and actively evolving area of treatment for patients who have not found sufficient benefit from approved therapies.

Any decision should be made with a neurologist who knows your full history, disease course, and goals. To learn more about how regenerative medicine works and whether it may be right for you, R3 Stem Cell offers free consultations at centers worldwide.

Contact Us

Why Dr. Hector is "Passionate" About the Word "Natural"

Consent alone is not sufficient. Donor mothers also undergo comprehensive medical screening, which typically includes:

What Does the Bioethics Community Say?